AstraZeneca and Merck & Co have entered into a collaborative agreement to develop two investigational anticancer compounds, MK-2206 from Merck’s portfolio and AZD6244 (ARRY-886) from the AstraZeneca stable. The collaboration brings together two companies with expertise in oncology.